News Releases

PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Non-brokered Private Placement

Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”)(CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that, further to its News Release of June 25, 2025 and July 8, 2025 it has rescheduled its annual general and special meeting from September 5, 2025 to September 29, 2025 at which the shareholders (the “PreveCeutical Shareholders”) of the Company will be asked to approve:  

1. the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the Company; 

2. the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the auditors of PreveCeutical for the financial year ending December 31, 2024 and 2025; 

3. a plan of arrangement under the provisions of Division 5 of Part 9 of the Business Corporations Act (British Columbia), pursuant to which the Company will distribute up to 12,000,000 common shares of BioGene Therapeutics Inc. (“BioGene”) to the PreveCeutical Shareholders; (the “Arrangement and Distribution”); and

4. the adoption of the PreveCeutical’s Omnibus Equity Incentive Plan.

Once the Arrangement and Distribution is complete, the PreveCeutical Shareholders will own shares in two companies: BioGene, which will focus on the development of the Dual Gene Therapy program, and PreveCeutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical believes that the Arrangement and Distribution is in the best interests of PreveCeutical and the PreveCeutical Shareholders for numerous reasons, including that separating PreveCeutical and BioGene will expand both PreveCeutical’s and BioGene’s potential shareholder base and access to capital for research, development and clinical trials by allowing investors that want specific ownership in the particular business of BioGene the opportunity to invest directly in BioGene rather than through PreveCeutical.

The Company also announces a non-brokered private placement (the “Offering”) of up to 25,000,000 units in the capital of the Company (the “Units”) at a price of $0.04 per Unit for gross proceeds of up to $1,000,000. Each Unit consists of one (1) common share of the Company (each, a “Share”) and one-half (1/2) of one Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase an additional Share (each, a “Warrant Share”) at an exercise price of $0.06 per Warrant Share for a period of two years from the closing of the Offering (the “Closing”).  Finder’s fees may be paid in connection with the Offering. 

The Company intends to use the aggregate gross proceeds from the sale of the Offering to pay outstanding payables, for operating expenses and for general working capital purposes. 

All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after the Closing. Completion of the Offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the Canadian Securities Exchange (the “CSE”).

The securities issued under the Offering have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organicand nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research anddevelopment programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com,follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer,

Chairman andChief Executive Officer

For further information, please contact:

Stephen Van Deventer: +1 604 306 9669

Or Investor Relationsir@preveceutical.com

Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the proposed Offering, the expectations of management regarding the use of proceeds of the Offering, closing conditions for the Offering, the expiry of hold periods for securities distributed pursuant to the Offering and other statements regarding the company's proposed business plans. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that: the Company may not complete the Offering on terms favorable to the Company or at all; the proceeds of the Offering may not be used as stated in this news release; the Company may be unable to satisfy all of the conditions to the Closing; and those additional risks set out in the Company’s public documents filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.